[go: up one dir, main page]

TN2013000390A1 - Bispecific binding molecules binding to vegf and ang2 - Google Patents

Bispecific binding molecules binding to vegf and ang2

Info

Publication number
TN2013000390A1
TN2013000390A1 TNP2013000390A TN2013000390A TN2013000390A1 TN 2013000390 A1 TN2013000390 A1 TN 2013000390A1 TN P2013000390 A TNP2013000390 A TN P2013000390A TN 2013000390 A TN2013000390 A TN 2013000390A TN 2013000390 A1 TN2013000390 A1 TN 2013000390A1
Authority
TN
Tunisia
Prior art keywords
ang2
vegf
binding
binding molecules
bispecific
Prior art date
Application number
TNP2013000390A
Other languages
English (en)
Inventor
Andreas Gschwind
Rene Georg Ott
Joachim Boucneau
Marie-Ange Buyse
Erik Depla
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45895502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000390(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TN2013000390A1 publication Critical patent/TN2013000390A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TNP2013000390A 2011-04-01 2013-09-26 Bispecific binding molecules binding to vegf and ang2 TN2013000390A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11160921 2011-04-01
PCT/EP2012/055901 WO2012131078A1 (fr) 2011-04-01 2012-03-30 Molécules de liaison bispécifiques se liant à vegf et à ang2

Publications (1)

Publication Number Publication Date
TN2013000390A1 true TN2013000390A1 (en) 2015-01-20

Family

ID=45895502

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000390A TN2013000390A1 (en) 2011-04-01 2013-09-26 Bispecific binding molecules binding to vegf and ang2

Country Status (36)

Country Link
US (4) US9527925B2 (fr)
EP (2) EP2694546B1 (fr)
JP (2) JP6023786B2 (fr)
KR (1) KR101907572B1 (fr)
CN (2) CN105820243A (fr)
AP (1) AP2013007085A0 (fr)
AR (1) AR085984A1 (fr)
AU (2) AU2012237234B2 (fr)
BR (1) BR112013025304B1 (fr)
CA (1) CA2827817C (fr)
CL (1) CL2013002623A1 (fr)
CO (1) CO6801639A2 (fr)
CY (1) CY1118339T1 (fr)
DK (1) DK2694546T3 (fr)
EA (2) EA036746B1 (fr)
EC (1) ECSP13013001A (fr)
ES (1) ES2606302T3 (fr)
HK (1) HK1225400A1 (fr)
HR (1) HRP20161689T1 (fr)
HU (1) HUE030148T2 (fr)
IL (1) IL227936B (fr)
LT (1) LT2694546T (fr)
MA (1) MA34979B1 (fr)
MX (2) MX337543B (fr)
MY (1) MY171007A (fr)
PE (1) PE20140448A1 (fr)
PH (1) PH12013502044A1 (fr)
PL (1) PL2694546T3 (fr)
PT (1) PT2694546T (fr)
RS (1) RS55361B1 (fr)
SG (2) SG193561A1 (fr)
SI (1) SI2694546T1 (fr)
TN (1) TN2013000390A1 (fr)
UA (1) UA114707C2 (fr)
UY (1) UY33998A (fr)
WO (1) WO2012131078A1 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
NZ628584A (en) * 2012-03-30 2016-04-29 Boehringer Ingelheim Int Ang2-binding molecules
UA120029C2 (uk) 2012-07-13 2019-09-25 Рош Глікарт Аг Спосіб зниження в'язкості біспецифічного антитіла до vegf/ang-2 та застосування такого антитіла для лікування судинних очних захворювань
CA2883807A1 (fr) * 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Combinaisons pharmaceutiques comprenant des liants doubles angiopoietine-2/dll4 et des agents anti-vegf-r
WO2014049100A1 (fr) * 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Combinaisons pharmaceutiques comprenant des liants doubles angiopoïétine-2/dll4 et des agents anti-vegf
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
SG11201705323WA (en) * 2015-01-16 2017-07-28 Academia Sinica Molecular constructs with targeting and effector elements
AR103477A1 (es) * 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
ES2913200T3 (es) 2015-03-31 2022-06-01 Sorriso Pharmaceuticals Inc Polipéptidos
WO2016156466A1 (fr) 2015-03-31 2016-10-06 Vhsquared Limited Construction peptidique comportant un lieur clivable par une protéase
CN107438620A (zh) * 2015-03-31 2017-12-05 韦斯夸尔德有限公司 多肽
WO2017020001A2 (fr) * 2015-07-29 2017-02-02 Allergan, Inc. Anticorps contenant seulement une chaîne lourde contre ang-2
JP2018523673A (ja) * 2015-08-14 2018-08-23 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Ｐｄｇｆに対する重鎖のみ抗体
SG10201911226QA (en) * 2015-09-23 2020-01-30 Genentech Inc Optimized variants of anti-vegf antibodies
AU2016351710B2 (en) * 2015-11-13 2023-08-03 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
UA122079C2 (uk) 2015-12-04 2020-09-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Поліпептид, що специфічно зв'язується з lrp5 і lrp6
IL264961B2 (en) * 2016-08-23 2025-02-01 Medimmune Ltd Antibodies against VEGF–A and their uses
CA3034574A1 (fr) 2016-08-23 2018-03-01 Medimmune Limited Anticorps anti-vegf-a et anti-ang2 et leurs utilisations
CN110072519A (zh) * 2016-12-14 2019-07-30 普罗根尼蒂公司 使用jak抑制剂治疗胃肠道疾病及装置
RU2648164C1 (ru) * 2016-12-19 2018-03-22 Федеральное государственное учреждение науки Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Селективный бифункциональный препарат на основе фрагментов одноцепочечных антител верблюжьих, нацеленный на опухолевые рецепторы cd47/erbb2, предназначенный для терапии злокачественных новообразований
WO2018114728A1 (fr) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Polythérapie par anticorps bispécifique anti-ang2/vegf et anticorps bispécifique anti-her2
EP3565839A4 (fr) 2017-01-05 2021-04-21 Gensun Biopharma Inc. Antagonistes de régulateur de point de contrôle
MA48760A (fr) 2017-05-31 2020-04-08 Boehringer Ingelheim Int Polypeptides ayant un effet antagoniste sur la signalisation wnt dans des cellules tumorales
WO2018220169A1 (fr) * 2017-06-02 2018-12-06 Boehringer Ingelheim International Gmbh Polythérapie anticancéreuse
JP7005772B2 (ja) 2018-02-06 2022-02-10 エフ．ホフマン－ラ ロシュ アーゲー 眼科疾患の処置
US12171764B2 (en) * 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
WO2020006511A1 (fr) 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Antagonistes trispécifiques
MX2021004774A (es) 2018-10-29 2021-08-24 Hoffmann La Roche Formulacion de anticuerpos.
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
CN114514243B (zh) 2019-06-21 2025-01-24 索瑞索制药公司 多肽
WO2020254827A1 (fr) 2019-06-21 2020-12-24 Vhsquared Limited Polypeptides
EP3990116A1 (fr) 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTAGONISTE ANTITUMORAL COMPOSÉ D'UN DOMAINE EXTRACELLULAIRE TGFß1 - RII MUTÉ ET D'UN ÉCHAFAUDAGE D'IMMUNOGLOBULINE
CN110452297B (zh) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用
WO2021119531A1 (fr) * 2019-12-11 2021-06-17 Cullinan Management, Inc. Anticorps anti-albumine sérique
CN115916818A (zh) 2019-12-11 2023-04-04 库利南肿瘤股份有限公司 抗cd19抗体和多特异性结合蛋白
WO2021155151A1 (fr) * 2020-01-29 2021-08-05 The Methodist Hospital System Ligands multivalents ciblant des récepteurs de surface cellulaire et plateforme de mesure de force pour leur fabrication
WO2021209458A1 (fr) 2020-04-14 2021-10-21 Ares Trading S.A. Traitement combiné du cancer
CA3189030A1 (fr) 2020-07-07 2022-01-13 Kanaph Therapeutics Inc. Proteines de fusion comprenant un inhibiteur de la voie du complement et un inhibiteur de l'angiogenese, et leur utilisation
CN116507627A (zh) 2020-11-02 2023-07-28 勃林格殷格翰国际有限公司 作为egfr抑制剂的经取代1h-吡唑并[4,3-c]吡啶及衍生物
EP4019548A1 (fr) * 2020-12-23 2022-06-29 Vrije Universiteit Brussel Vhh anti lag3 et leurs utilisations
WO2022171109A1 (fr) * 2021-02-10 2022-08-18 上海济煜医药科技有限公司 Anticorps anti-vegf et son utilisation
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
WO2022256820A1 (fr) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Antagonistes multispécifiques
TW202302633A (zh) * 2021-06-04 2023-01-16 大陸商信達生物製藥（蘇州）有限公司 結合ｖｅｇｆ和ａｎｇ２的雙特異性結合分子以及其用途
AU2022327397A1 (en) * 2021-08-13 2024-03-14 Innovent Biologics (Suzhou) Co., Ltd. Anti-vegf a and -vegf c bispecific antibody and use thereof
WO2023035226A1 (fr) * 2021-09-10 2023-03-16 深圳康哲医药发展有限公司 Anticorps anti-ang2, son procédé de préparation et son utilisation
CU24770B1 (es) * 2021-12-15 2025-09-01 Ct Ingenieria Genetica Biotecnologia Polipéptidos que se unen al factor de crecimiento del endotelio vascular y al factor básico de crecimiento de fibroblastos
KR20230105972A (ko) 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
EP4574846A1 (fr) 2022-09-14 2025-06-25 Quaerite Biopharm Research (Beijing) Co., Ltd. Protéine de fusion anti-vegfa, son procédé de préparation et son utilisation
JP2025534252A (ja) 2022-09-14 2025-10-15 尋済生物科技（北京）有限公司 抗ｖｅｇｆａ抗体またはその抗原結合フラグメント、およびその使用
CN120322464A (zh) * 2022-12-01 2025-07-15 信达生物制药(苏州)有限公司 三特异性融合蛋白及其用途
WO2024114746A1 (fr) * 2022-12-01 2024-06-06 信达生物制药(苏州)有限公司 Préparation contenant une molécule de liaison bispécifique se liant à vegf et à ang2 et son utilisation
WO2024178730A1 (fr) * 2023-03-02 2024-09-06 清华大学 Médicament protéique cristallisable anti-vegf intravitréen pour inhiber la néovascularisation choroïdienne
WO2025111816A1 (fr) * 2023-11-28 2025-06-05 Eluminex Biosciences Limited Protéines de fusion multispécifiques ciblant des facteurs angiogéniques, inflammatoires et/ou fibrotiques
WO2025189977A1 (fr) * 2024-03-13 2025-09-18 寻济生物科技（北京）有限公司 Construction de fusion anti-vegfa, son procédé de préparation et son utilisation
WO2025219504A1 (fr) 2024-04-19 2025-10-23 F. Hoffmann-La Roche Ag Traitement de maladies ophtalmologiques

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE452975T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
US5408535A (en) 1993-09-07 1995-04-18 Miles Inc. Video test strip reader and method for evaluating test strips
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DK1325932T5 (da) 1997-04-07 2005-10-03 Genentech Inc Anti-VEGF antistoffer
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
MXPA03006358A (es) 2001-01-17 2004-12-02 Trubion Pharmaceuticals Inc Proteinas de fusion dominio de enlace-inmunoglobulina.
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
JP2005518805A (ja) 2002-03-01 2005-06-30 ボール・ホーティカルチャラル・カンパニー 花組織においてトランスジーンを発現させるためのｌｉｓプロモーター
AU2003267563A1 (en) 2002-09-10 2004-04-30 Lorantis Limited Pharmaceutical composition and medical treatments comprising notch ligand proteins
US20060228355A1 (en) 2003-11-07 2006-10-12 Toon Laeremans Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
EP1558646A2 (fr) 2002-11-08 2005-08-03 Ablynx N.V. Anticorps a domaine unique diriges contre un interferon gamma et leurs utilisations
US20050043220A1 (en) 2002-11-08 2005-02-24 Guyer David R. Methods and compositions for treating macular degeneration
NZ540196A (en) 2002-11-08 2008-09-26 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
WO2004060965A2 (fr) 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Polymeres a terminaison maleimide hydrolytiquement stables
US9028816B2 (en) 2003-01-10 2015-05-12 Ablynx N.V. Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
DK1639011T3 (da) 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
NZ601544A (en) 2003-08-27 2013-11-29 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
BRPI0518151A2 (pt) 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
CN101120020A (zh) 2004-12-17 2008-02-06 健泰科生物技术公司 先前的疗法失败的患者中自身免疫病的抗血管发生疗法
JP4884395B2 (ja) 2004-12-21 2012-02-29 アストラゼネカ エービー アンジオポエチン−２に対する抗体およびそれらの使用
US8188223B2 (en) * 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
WO2007053186A2 (fr) 2005-05-31 2007-05-10 Labnow, Inc. Méthodes et compositions en rapport avec la détermination et l’utilisation de la numération de globules blancs
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007028110A2 (fr) 2005-09-01 2007-03-08 Vasgene Therapeutics, Inc. Methodes d'utilisation et d'identification de modulateurs de delta-like 4
WO2007043109A1 (fr) 2005-09-30 2007-04-19 Fujitsu Limited Stockage d’informations
US20090123474A1 (en) 2005-12-15 2009-05-14 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
WO2007070671A2 (fr) 2005-12-16 2007-06-21 Regeneron Pharmaceuticals, Inc. Procedes therapeutiques pour l'inhibition de croissance tumorale avec des antagonistes dll4
AU2007209202A1 (en) 2006-01-24 2007-08-02 Domantis Limited Ligands that bind IL-4 and/or IL-13
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US7570881B2 (en) 2006-02-21 2009-08-04 Nokia Corporation Color balanced camera with a flash light unit
US20070269422A1 (en) * 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
AU2007319672B2 (en) 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
US20080014196A1 (en) 2006-06-06 2008-01-17 Genentech, Inc. Compositions and methods for modulating vascular development
SG174033A1 (en) 2006-08-07 2011-09-29 Regeneron Pharma Therapeutic methods for treating vascular eye disorders with dll4 antagonists
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
CA2663042A1 (fr) 2006-09-08 2008-03-13 Ablynx N.V. Proteines a demi-vie longue se liant a l'albumine serique
JP2010505435A (ja) 2006-10-11 2010-02-25 アブリンクス エン．ヴェー． 本質的にｐＨに非依存的に血清タンパク質に結合するアミノ酸配列、それを含む化合物、およびその使用
MX2009004027A (es) 2006-10-20 2009-09-28 Schering Corp Anticuerpos anti factor de crecimiento endotelial vascular completamente humanos y metodos de uso.
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US20110118185A9 (en) 2007-02-21 2011-05-19 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
US10259860B2 (en) 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
CA2681974C (fr) 2007-03-29 2019-12-31 Genmab A/S Anticorps bispecifiques et procedes de production de ceux-ci
GB0709333D0 (en) 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
KR20100040840A (ko) 2007-06-06 2010-04-21 도만티스 리미티드 폴리펩티드，항체 가변 도메인 및 길항제
MX2009013137A (es) 2007-06-06 2010-04-30 Domantis Ltd Metodos para seleccionar polipeptidos resistentes a la proteasa.
EP2014680A1 (fr) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Dérivés d'anticorps bi-spécifiques ou tri-spécifiques trivalents, recombinants, à simple chaîne
RU2010120674A (ru) 2007-10-22 2011-11-27 Шеринг Корпорейшн (US) Полностью человеческие анти-vegf-антитела и способы их применения
MX2010005603A (es) 2007-11-26 2010-08-02 Bayer Schering Pharma Ag Anticuerpos antimesotelina y usos de los mismos.
WO2009095489A2 (fr) 2008-02-01 2009-08-06 Ablynx N.V. Séquences d'acides aminés améliorées dirigées contre il-6r et polypeptides les comprenant pour le traitement de maladies et troubles associés à une signalisation facilitée par il-6
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
AU2009221106A1 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
HUE035182T2 (hu) 2008-03-18 2018-05-02 Genentech Inc Anti-HER2 antitest-hatóanyag-konjugátum és pertuzumab kombinációi
AU2009235467A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CA2722466A1 (fr) 2008-04-29 2009-11-05 Tariq Ghayur Immunoglobulines a double domaine variable et utilisations
SI2285408T1 (sl) 2008-06-05 2019-02-28 Ablynx N.V. Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni
KR101737466B1 (ko) 2008-06-25 2017-05-18 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
CA2734905A1 (fr) 2008-09-03 2010-03-11 Jenny M. Bostrom Anticorps multispecifiques
EP2344536A1 (fr) 2008-09-19 2011-07-20 MedImmune, LLC Anticorps dirigés contre dll4 et leurs utilisations
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CA2746395C (fr) 2008-12-10 2019-07-09 Ablynx N.V. Polypeptides comportant des sequences d'acides amines dirigees contre tie 2 servant au traitement de maladies et de troubles relatifs a l'angioggenese
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
CN104374932A (zh) 2009-01-13 2015-02-25 Fio公司 与电子设备和快速诊断测试中的测试盒结合使用的手持诊断测试设备
WO2010124009A2 (fr) 2009-04-21 2010-10-28 Schering Corporation Anticorps anti-vegf entièrement humains et méthodes d'utilisation de ceux-ci
EP2424567B1 (fr) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
WO2010148223A2 (fr) 2009-06-17 2010-12-23 Facet Biotech Corporation Anticorps anti-vegf et leurs utilisations
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
UY32917A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
SG183414A1 (en) 2010-02-23 2012-09-27 Genentech Inc Anti-angiogenesis therapy for the treatment of ovarian cancer
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
WO2012012499A1 (fr) 2010-07-20 2012-01-26 Nurx Pharmaceuticals, Inc. Système de lecteur optique
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
RU2013125479A (ru) 2010-11-02 2014-12-10 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
MX2013013940A (es) 2011-05-27 2014-01-23 Vital Art And Science Inc Metodo para tratamiento de los transtornos de la vision.
PT2758073T (pt) 2011-09-23 2019-02-01 Oncomed Pharm Inc Agentes de ligação a vegf/dll4 e utilizações dos mesmos
NZ628584A (en) * 2012-03-30 2016-04-29 Boehringer Ingelheim Int Ang2-binding molecules
US9292583B2 (en) * 2012-11-27 2016-03-22 Google Inc. Method of displaying search results

Also Published As

Publication number Publication date
US20220017642A1 (en) 2022-01-20
HK1190412A1 (zh) 2014-07-04
CO6801639A2 (es) 2013-11-29
HK1225400A1 (zh) 2017-09-08
UA114707C2 (uk) 2017-07-25
LT2694546T (lt) 2016-11-10
EA201301108A1 (ru) 2014-03-31
BR112013025304A2 (pt) 2017-06-06
CN105820243A (zh) 2016-08-03
KR101907572B1 (ko) 2018-10-15
EP3144322A2 (fr) 2017-03-22
IL227936A0 (en) 2013-09-30
EP2694546A1 (fr) 2014-02-12
JP2017023152A (ja) 2017-02-02
CA2827817A1 (fr) 2012-10-04
KR20140018317A (ko) 2014-02-12
IL227936B (en) 2018-06-28
NZ614249A (en) 2015-05-29
AU2012237234B2 (en) 2016-10-20
MX2013010949A (es) 2014-06-06
PL2694546T3 (pl) 2017-03-31
RS55361B1 (sr) 2017-03-31
ECSP13013001A (es) 2013-12-31
US20170247475A1 (en) 2017-08-31
JP2014515602A (ja) 2014-07-03
US10414828B2 (en) 2019-09-17
AP2013007085A0 (en) 2013-08-31
AR085984A1 (es) 2013-11-13
AU2017200237B2 (en) 2018-05-17
US20130078248A1 (en) 2013-03-28
CY1118339T1 (el) 2017-06-28
JP6023786B2 (ja) 2016-11-09
EP3144322A3 (fr) 2017-05-31
PE20140448A1 (es) 2014-04-13
AU2017200237A1 (en) 2017-02-02
CL2013002623A1 (es) 2014-02-14
MA34979B1 (fr) 2014-03-01
SG193561A1 (en) 2013-11-29
BR112013025304B1 (pt) 2022-10-11
HRP20161689T1 (hr) 2017-02-24
US9527925B2 (en) 2016-12-27
MX343440B (es) 2016-11-07
CA2827817C (fr) 2020-12-15
EA036746B1 (ru) 2020-12-16
SG10201602373TA (en) 2016-05-30
CN103562222B (zh) 2016-04-06
UY33998A (es) 2012-09-28
CN103562222A (zh) 2014-02-05
HUE030148T2 (en) 2017-04-28
WO2012131078A1 (fr) 2012-10-04
MX337543B (es) 2016-03-10
JP6297657B2 (ja) 2018-03-20
SI2694546T1 (sl) 2017-01-31
US11161916B2 (en) 2021-11-02
EP2694546B1 (fr) 2016-09-21
ES2606302T3 (es) 2017-03-23
PT2694546T (pt) 2016-12-28
MY171007A (en) 2019-09-23
PH12013502044A1 (en) 2013-12-16
US20200010569A1 (en) 2020-01-09
EA025148B1 (ru) 2016-11-30
DK2694546T3 (en) 2016-12-05
AU2012237234A1 (en) 2013-09-05
EA201600338A1 (ru) 2016-09-30

Similar Documents

Publication Publication Date Title
TN2013000390A1 (en) Bispecific binding molecules binding to vegf and ang2
IN2014DN06904A (fr)
TN2012000144A1 (en) Dll4-binding molecules
PH12013500410B1 (en) Vegf-binding molecules
TN2012000145A1 (en) Bispecific binding molecules for anti-angiogenesis therapy
WO2014004549A3 (fr) Protéines de liaison anti-mésothéline
TN2013000389A1 (en) BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2
PH12014502527B1 (en) St2 antigen binding proteins